ClinicalTrials.gg
RecruitingNCT06284889DepActiveUpdated Oct 15, 2026

Behavioral Activation for the Treatment of Depression in Older Adults

An interventional study of Behavioural activation and Treatment as usual (TAU) in Depression, sponsored by Uppsala University. Recruiting at 2 sites in Sweden. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Uppsala University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 15, 2026Now RecruitingResults publication added+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Depression by Uppsala University — 5 open to participants now, 5 under way, none of them phase 3. Depression · Uppsala University.

Planned enrollment
5th of 13
81 · median 60
Started
2024
with 3 others
No phase
12 of 17
4 open now
Registered
12th of 17
by date

Among the 17 studies in Depression by Uppsala University, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 12th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

5 of the 17 studies in Depression by Uppsala University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depression by Uppsala University, or all of them as a file.
02

Study summary

Depression affects between 5-15% of adults ≥ 65 years in Sweden. Depression in older adults reduces functional ability and quality of life, and increases the risk for morbidity, loneliness, and suicide. Psychological treatment is recommended as a first-line treatment for depression, which about 3% of older adults with depression in Sweden report receiving. One effective psychological treatment is behavioral activation, which reduces depressive symptoms by increasing enjoyable, meaningful and important activities, for example exercise and social activities. The research group conducted a pilot study of telephone based behavioral activation for isolated older adults with depression during the COVID-19 pandemic. The intervention consisted of four telephone calls, and the results showed a significant decrease in depressive symptoms, with maintained effects for six months.

250 individuals will participate in the study. Half of the participants will be randomised to start the intervention immediately, while the other half of the participants will be randomized to a control group receiving treatment as usual at their respective primary care center. Participants will be asked to fill in questionnaires before, after treatment. Questionnaires will also be sent 3- and 6 months after treatment to follow up on the results. Patients will be asked to wear an accelerometer for 5-7 days to record their activity level at baseline, post-intervention and after 3-months. A smaller group of participants (10-15) will be asked to participate in a more detailed interview about how they experienced the treatment.

Read the detailed description

In Sweden, depression among the elderly is a major public health concern. Major depression occurred in 5-15 % of the older population in Sweden, and one third of the women and a fifth of the men 65 years and older reported subclinical depressive symptoms. Several mental health experts raise concerns that there will be an increase of psychiatric illness during and after COVID-19, particularly among the elderly.

Depression in older individuals can be treated with antidepressant medication, psychological interventions and physical activity. However, the majority of the older individuals state that they would prefer psychological treatments to medication, which poses a challenge during COVID-19 as such treatments are often delivered face-to-face. Psychological treatments delivered via the Internet are as efficacious as face-to-face, but only 3-4% of the individuals 65 years and above in Sweden use digital applications that replace physical healthcare visits.

The purpose of this randomised controlled multicenter study is to evaluate the effects and outcomes of a telephone-delivered Behavioral Activation-treatment for older adults with depression in primary care within the framework of the research project DepActive. Our study specifically aims to: 1. investigate the effect of a telephone-delivered BA-treatment for older adults with depression in primary care with regards to a. depressive symptoms (primary outcome measure) b. depression diagnosis c. anxiety symptoms d. quality of life e. activity level f. functional ability g. cognitive function h. loneliness i. self-efficacy j. cost effectiveness k. care consumption including pharmacological treatment 2. explore patients' and therapists' experiences of the treatment 3. investigate to which extent the BA-treatment corresponds to person-centered care 4. investigate the mediating role of type of activity and level of physical activity with regards to improvement in depressive symptoms 5. investigate whether the intervention impacts the need for community healthcare services for participants utilizing such services.

The study is a multi-center randomised controlled clinical trial in primary care in the Swedish county councils of Vastmanland, Uppsala and Sormland.

Participants will be recruited from multiple primary care centers in each region. If the participant is enrolled in the study, the study therapist performs the randomisation by using an online randomisation software with a 1:1, random-blocks sequence. The participants are randomised consecutively to two arms: control group or intervention group. The control group will receive treatment as usual (TAU) in primary care, and the intervention group will receive TAU with the addition of a five-session telephone-based BA-intervention over an eight-week period.

03

Conditions studied

  • Depression

Keywords

  • Behavioral activation
  • Older adults
  • Activity
  • Primary care
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants should fulfill criteria for current major depressive episode or sub-threshold depressive episode.
  • Eligible participants should be 65 years or older, should be fluent in spoken and written Swedish to understand the treatment materials, have access to telephone, and be interested in participating in the trial.

Exclusion criteria

Exclusion Criteria:

  • Severe depression, elevated suicide risk, current substance use disorder, current or previous manic or hypomanic episodes, current psychotic disorder, and current diagnosis of minor or major neurocognitive disorder or suspected neurocognitive disorder with \< 24 points on the number 3, MMSE-NR3.
  • ongoing psychotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    Treatment

    Brief Behavioral Activation

    Behavioral: Behavioural activation · Other: Treatment as usual (TAU)

  • Placebo comparator
    Treatment as usual (TAU)

    Treatment as usual regarding depression received at their primary care centre.

    Other: Treatment as usual (TAU)

Interventions

  • BehavioralBehavioural activation

    Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log; Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week. Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month. Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan.

  • OtherTreatment as usual (TAU)

    Treatment as usual regarding depression received at their primary care centre.

06

What researchers measure

Primary outcomes

  1. Change from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-S

    Depressive symptoms measured with the Montgomery-Asberg Depression Rating Self-rating Scale, MADRS-S. MADRS-S is a nine-item questionnaire used to measure severity of depression. The score ranges from 0-54. High scores indicate more depressive symptoms.

    Time frame: Baseline; Intervention 1 Week 9

Secondary outcomes

  1. Change from baseline in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINI

    MINI is a structured clinical interview used to assess the presence/absence of common psychiatric disorders.

    Time frame: Baseline; Intervention 1 Week 9

  2. Change from baseline in Physical Activity level

    Physical Activity levels measured with accelerometer, ActiGraph GT3X. Self rated physical activity levels measured with Frandin/Grimby activity scale, which is a 6 item scale. The score ranges from 0-6. High scores indicate high levels of physical activity.

    Time frame: Baseline; Intervention 1 Week 9

  3. Change from baseline in anxiety symptoms using the Geriatric Anxiety Scale - 10 item (GAS-10) is a self-rating scale designed to capture anxiety specifically in older adults, with items reflecting affective-, cognitive- and somatic anxiety symptoms.

    Anxiety symptoms measured with the Geriatric Anxiety Scale -10 version. Self rating symptoms. The score ranges from 0-10. High scores indicate high levels of anxiety.

    Time frame: Baseline; Intervention 1 Week 9

  4. Change from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODAS

    WHODAS-12 is a 12-item questionnaire used to assess disability due to health conditions. The total score ranges from 0-48. High scores indicate high levels of disability.

    Time frame: Baseline; Intervention 1 Week 9

  5. Change from baseline in self rated quality of life using the EuroQol-5 Dimensions-5 Level Scale, EQ-5D-5L

    The EuroQol-5 Dimensions-5 Level Scale, EQ-5D-5L is a 5-item scale. The scale describes health in five dimensions.

    Time frame: Baseline; Intervention 1 Week 9

  6. Changes from baseline in Self Efficacy measured with the New General Self-Efficacy Scale, S-GSE.

    Self efficacy measured with the New General Self-Efficacy Scale, S-GSE. The scale consists of 10 items. Total score ranges from 10-40. High scores indicates high levels of self efficacy.

    Time frame: Baseline; Intervention 1 Week 9

  7. Changes from baseline in loneliness measured with the UCLA Loneliness Scale version 3, UCLA-LS-3.

    Loneliness measured with the UCLA Loneliness Scale version 3, UCLA-LS-3. This is a 20 item scale. Total score ranges from 20-80. High scores indicates low levels of loneliness.

    Time frame: Baseline; Intervention 1 Week 9

  8. Diagnostic accuracy

    Area under curve, sensitivity, specificity

    Time frame: Baseline; Week 0

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Pellas J, Renner F, Ji JL, Damberg M. Telephone-Based Behavioral Activation with Mental Imagery for Depression in Older Adults in Isolation During the covid-19 Pandemic: Long-term Results from a Pilot Trial. Clin Gerontol. 2023 Jan-Dec;46(5):801-807. doi: 10.1080/07317115.2022.2124899. Epub 2022 Sep 20. PubMed 36128612 ↗
  • Pellas J, Renner F, Ji JL, Damberg M. Telephone-based behavioral activation with mental imagery for depression: A pilot randomized clinical trial in isolated older adults during the Covid-19 pandemic. Int J Geriatr Psychiatry. 2022 Jan;37(1):10.1002/gps.5646. doi: 10.1002/gps.5646. Epub 2021 Nov 10. PubMed 34729823 ↗
  • Pellas J, Damberg M. Accuracy in detecting major depressive episodes in older adults using the Swedish versions of the GDS-15 and PHQ-9. Ups J Med Sci. 2021 Oct 20;126. doi: 10.48101/ujms.v126.7848. eCollection 2021. PubMed 34754407 ↗
  • Bystrom E, Wennlof B, Johansson I, Lonnberg L, Arkkukangas M, Pellas J, Damberg M. DepActive: study protocol for a randomised controlled multicentre trial of telephone-delivered behavioural activation for the treatment of depression in older adults in primary care. Trials. 2024 Oct 5;25(1):659. doi: 10.1186/s13063-024-08521-y. PubMed 39369239 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2027 → Nov 2026 and completion Dec 2028 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 29, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Nov 15, 2026was Dec 2027
CompletionEst.
Nov 15, 2026was Dec 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added. Uppsala university is now Not yet recruiting
Show site
  • Dept Public Health and caring sciences, Uppsala university · Uppsala, Sweden
Oct 15, 2026
Primary completion
Dec 31, 2027→Nov 15, 2026
Oct 15, 2026
Study completion
Dec 31, 2028→Nov 15, 2026
Oct 15, 2026
Enrollment
250→81
Oct 15, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-SBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
Oct 15, 2026
Publications
Results publication added: Bystrom E, Wennlof B, Johansson I, Lonnberg L, Arkkukangas M, Pellas J, Damberg M. DepActive: study protocol for a randomised controlled multicentre trial of t… PubMed 39369239 ↗
Oct 15, 2026
Secondary outcomes
7 time frame changed
What changed in the outcomes
  • Time frameChange from baseline in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINIBaseline; Intervention 1 Week 9; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChange from baseline in Physical Activity levelBaseline; Intervention 1 Week 9; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChange from baseline in anxiety symptoms using the Geriatric Anxiety Scale - 10 item (GAS-10) is a self-rating scale designed to capture anxiety specifically in older adults, with items reflecting affective-, cognitive- and somatic anxiety symptoms.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChange from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODASBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChange from baseline in self rated quality of life using the EuroQol-5 Dimensions-5 Level Scale, EQ-5D-5LBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChanges from baseline in Self Efficacy measured with the New General Self-Efficacy Scale, S-GSE.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
  • Time frameChanges from baseline in loneliness measured with the UCLA Loneliness Scale version 3, UCLA-LS-3.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
Oct 15, 2026
Contact
Study contact changed: m•••@pubcare.uu.se→m•••@uu.se; added l•••@regionvastmanland.se. See the current contact
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Publications Results publication added: Bystrom E, Wennlof B, Johansson I, Lonnberg L, Arkkukangas M, Pellas J, Damberg M. DepActive: study protocol for a randomised controlled multicentre trial of t… PubMed 39369239 ↗
    1 site added. Uppsala university is now Not yet recruiting
    Show site
    • Dept Public Health and caring sciences, Uppsala university · Uppsala, Sweden
    Primary completion Dec 31, 2027→Nov 15, 2026
    Study completion Dec 31, 2028→Nov 15, 2026
    Enrollment 250→81
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-SBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    Secondary outcomes 7 time frame changed
    What changed in the outcomes
    • Time frameChange from baseline in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINIBaseline; Intervention 1 Week 9; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChange from baseline in Physical Activity levelBaseline; Intervention 1 Week 9; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChange from baseline in anxiety symptoms using the Geriatric Anxiety Scale - 10 item (GAS-10) is a self-rating scale designed to capture anxiety specifically in older adults, with items reflecting affective-, cognitive- and somatic anxiety symptoms.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChange from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODASBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChange from baseline in self rated quality of life using the EuroQol-5 Dimensions-5 Level Scale, EQ-5D-5LBaseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChanges from baseline in Self Efficacy measured with the New General Self-Efficacy Scale, S-GSE.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    • Time frameChanges from baseline in loneliness measured with the UCLA Loneliness Scale version 3, UCLA-LS-3.Baseline; Intervention 1 Week 9; 3 months post-intervention; 6 months post-intervention. → Baseline; Intervention 1 Week 9
    Contact Study contact changed: m•••@pubcare.uu.se→m•••@uu.se; added l•••@regionvastmanland.se. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06284889
Lead sponsor
Uppsala University
Collaborators
Västmanland County Council, Sweden, Sormland County Council, Sweden, Uppsala County Council, Sweden
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 4, 2024
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

Mattias Damberg, MD
Contact
mattias.damberg@uu.se
+46739480910
Mattias Damberg, MD, Associate Professor
principal investigator · Uppsala university, Dept. Public Care and Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion